The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

Researchers from Bonn and Erlangen identify the protein MLC1 as a target antigen in multiple sclerosis (MS); a chronic ...

Cabaletta Bio (CABA) announced new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel, or rese-cel, ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Feb. 8, 2024 — Researchers have discovered a previously unknown ability of a group of immune system cells, known as Atypical B cells (ABCs ... Lupus Erythematosus (SLE): New Genetic Findings ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

The manuscript addresses the 3D chromatin architecture in monocytes from patients with alcohol-associated hepatitis and its relationship to enhanced transcription of innate immune genes. While the ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.